Navigation Links
Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohn's Patients
Date:5/20/2008

is in whom an adequate course of treatment cannot be confirmed.

Serious infections, sepsis, and cases of opportunistic infections, including fatalities, have been reported in patients receiving TNF blockers, including Cimzia(R). Infections have been reported in patients receiving Cimzia(R) alone or in conjunction with immunosuppressive agents. Do not initiate treatment with Cimzia(R) in patients with active infections, including chronic or localized infections. Patients who develop a new infection while undergoing treatment with Cimzia(R) should be monitored closely. Discontinue administration of Cimzia(R) if a patient develops a serious infection. Exercise caution when considering the use of Cimzia(R) in patients with a history of recurrent infection, concomitant immunosuppressive therapy, or underlying conditions that may predispose them to infections, or patients who have resided in regions where tuberculosis and histoplasmosis are endemic.

Use of TNF blockers, including Cimzia(R), may increase the risk of reactivation of hepatitis B virus (HBV) in patients who are chronic carriers of this virus. Some cases have been fatal. Evaluate patients at risk for HBV infection for prior evidence of HBV infection before initiating Cimzia(R) therapy. Exercise caution in prescribing Cimzia(R) for patients identified as carriers of HBV. Patients who are carriers of HBV and require treatment with Cimzia(R) should be closely monitored for clinical and laboratory signs of active HBV infection throughout therapy and for several months following termination of therapy. In patients who develop HBV reactivation, discontinue Cimzia(R) and initiate effective anti-viral therapy with appropriate supportive treatment.

During controlled and open-labeled portions of Cimzia(R) studies of Crohn's disease and other investigational uses, malignancies were observed at a rate (95% confidence interval) of 0.6 (0.4, 0.8) per 100 patient-years among 4,650 Cimzia(R)-treated patie
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. UCB Launches CIMplicity(TM) Program to Enhance Treatment Support for Cimzia(R) (certolizumab pegol) Patients and Caregivers
2. FDA Approval of Cimzia(R) for Crohns Disease Represents Latest Milestone for Nektars PEGylation Technology Platform
3. AlphaRx Provides Corporate and Development Update
4. PA Health Department Provides Hepatitis B Vaccinations, Discusses Risk Factors
5. Cipher provides regulatory update for CIP-TRAMADOL ER
6. Innolife Pharma Provides Initial Update on Negotiations for Significant Product Joint Venture
7. InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results
8. Revised AVMA Policy on Castrating and Dehorning Cattle Provides Additional Guidance for Managing Pain
9. Dubai Provides Aid for Cyclone Nargis Victims In Myanmar
10. New Evidence Provides Clinicians With Better Tools to Help Smokers Quit
11. Cholera study provides exciting new way of looking at infectious disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2008)...e deadly traitors, good cells gone bad. They evade...f as organisms that pose no threat. , But resear...l Hill,s Eshelman School of Pharmacy are working o..., an associate professor of molecular pharmaceutic...bacterial elements in a cancer tumor in order to e...
(Date:8/20/2008)...al (MGH) investigators have found that infusions o...rotect gastrointestinal tissue from autoimmune att...n the journal Stem Cells , the team from the MGH ...enchymal stem cells (MSCs), known to control sever...ion of the gastrointestinal lining in mice with a ...
(Date:8/20/2008)...swire-USNewswire/ -- Yesterday evening,Congresswo...spital after,suffering an aneurysm while driving h...time Rep. Tubbs Jones, condition has stabilized an...day,s condition followed a full day of activity, i...al reform, scheduled for September 4, 2008,at Clev...
(Date:8/20/2008)...LEgirl.com Send Four Girls to My Beauty Camp ... Aug. 20 /PRNewswire/ -- Retin-A Micro(R) PUMP has...irl.com to send four contest,winners later this su...,California. With the new school year approaching,...e successful women by helping them build,confidenc...
Breaking Medicine News(10 mins):Health News:UNC researcher aims to 'unmask' cancer cells to trigger body's immune system 2Health News:Bone marrow stem cells may help control inflammatory bowel disease 2Health News:Bone marrow stem cells may help control inflammatory bowel disease 3Health News:Special Summer Camp Helps Girls Recognize Inner and Outer Beauty 2Health News:Special Summer Camp Helps Girls Recognize Inner and Outer Beauty 3Health News:Special Summer Camp Helps Girls Recognize Inner and Outer Beauty 4Health News:Special Summer Camp Helps Girls Recognize Inner and Outer Beauty 5
...ut on high alert following the detection of the de...y. // The officials have been instructed to keep a... and poultry into the territory. The proposed mov...with China with respect to illegal trafficking of ...
... Mental Health Foundation, even as the UK seeks to...earch // is to find out how much importance men ...gard to finding out if men would choose to lose th...me, and as to whether they merely enjoy watching t...
...ld be a common gene which gives rise to Alzheimer'...he // Indiana University School of Medicine. This ...a family disease. Genetic information is sought fr...lzheimer's disease is prevalent in two or more mem...
... in treating wet age related macular degeneration ...cula. Wet age related macular degeneration is caus...cula region of the eye, macula is present in the r...ye sight. The degenerative disease is caused by t...
Other Medicine News:Health News:Bird Flu Threat Prompts Tightened Security Across Hong Kong Border 2
(Date:8/19/2008)...swire/ -- Addrenex Pharmaceuticals (, http://www.a... month to,further its goal of identifying and deve...r the next 18 months., The fast-paced timeline th...,s recent successes in developing two new drugs, C...order and CloniBID for hypertension,over the past...
(Date:8/19/2008)...re-FirstCall/ -- Vical Incorporated,(Nasdaq: VICL...he Karolinska,Institute, a leading European medica...ious Disease Control (SMI), a governmental expert ...with the Biojector(R) 2000,needle-free injection s...CT) for a multivalent preventive DNA vaccine again...
(Date:8/18/2008)... /- Oramed,Pharmaceuticals,...a developer,of oral delivery systems, announced to...to Assess the Safety, Pharmacokinetics (PK) and,Ph...ons in Healthy,Subjects," has been chosen for pres...e European Association for the Study of Diabetes (...
(Date:8/17/2008)...Xinhua-- Pharmaxis,(ASX: PX...votal Phase 3,clinical trial of Bronchitol for the...ent., The first efficacy data from the trial is e...009. The trial commenced its dosing phase in,April...50 subjects in June,2008 and closed today with 325...
Breaking Medicine Technology:Addrenex Pharmaceuticals' New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation 2Addrenex Pharmaceuticals' New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation 3Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 2Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 3Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 4Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 5Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome) 2Bronchitol Phase 3 Cystic Fibrosis Trial Completes Recruitment 2Purchase Agreement for Antibody Manufacturing Facility Receives Antitrust Clearance 3543 1Purchase Agreement for Antibody Manufacturing Facility Receives Antitrust Clearance 3543 2Aflac Incorporated to Present at the Raymond James 29th Annual Institutional Investors Conference 12824 1Aflac Incorporated to Present at the Raymond James 29th Annual Institutional Investors Conference 12824 2QED International Associates Announces Changes to the HealthShares 28TM 29 GI Gender Health Index 12822 1ARJO Inc Launches Two Innovative Products and New Campaign 12820 1
...RE)--Jun 25, 2007 - HepaLife Technologies, Inc.,(O...ed that new,data presented at an international inf...ife,s patented PBS-1 cell line outperforms,current...virus,inside its cells. The most important step to...ne against a targeted virus is the,ability to effi...
...es 75% of patients receiving highest dose,achieves...e 25, 2007 /PRNewswire-FirstCall/ -- According to,...ssions of the,American Diabetes Association (ADA) ...t liraglutide, a once- daily dose of human,GLP-1 a...eatment of,type 2 diabetes significantly improved ...
Other Medicine Technology:HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 2HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 3HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 4HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 5HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 6Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog,Liraglutide, Brings Patients to A1c Target 2Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog,Liraglutide, Brings Patients to A1c Target 3Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog,Liraglutide, Brings Patients to A1c Target 4
...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
Medicine Products: